R
andomized controlled trials (RCTs) have demonstrated that therapies targeting tumor necrosis factor (TNF) and a₄b₇ integrin are effective when given as monotherapy in inducing and/or maintaining remission in patients with ulcerative colitis (UC) or Crohn's disease (CD), but data from RCTs are less clear on whether concomitant immunomodulator (IM) therapy confers additional benefit. In CD, RCT data are mixed, 1, 2 as are results of systematic reviews and meta-analyses, showing no benefit overall, 3 minimal benefit with individual agents, 4 and comparative benefit over some monotherapies but not others. 5 For example, concomitant azathioprine with infliximab is more effective than either drug alone in patients with CD naive to both drugs, 2 but whether combination therapy is more effective than monotherapy with infliximab in nonnaive patients, or with other approved biologic drugs in any population, remains unknown. In UC, RCTs have shown that the benefit may be limited to specific populations, 6 whereas systematic reviews suggest no benefit at all. 7 Before the full publication of the SONIC trial in 2010, 2 we used the RAND/UCLA Appropriateness Method to determine appropriateness of concomitant IM and anti-TNF therapy in patients with CD. 8 Given subsequent changes in the inflammatory bowel disease (IBD) treatment paradigm and evidence base, we revisited this question and expanded our purview to consider appropriateness of concomitant IM with anti-TNF and antiintegrin therapies in both CD and UC.
Methods
The RAND/UCLA Appropriateness Method was applied as described previously. 8 Briefly, a full text manuscripts on the use of concomitant IM and biologic therapy in CD and UC published since our review from our prior work, 8 were presented to an international panel of 11 members of the Building Research in Inflammatory Bowel Disease Globally group (www. BRIDGeIBD.com). These publications included our original manuscript and supplementary literature review, 8 the American Gastroenterological Association technical review on the role of IMs and anti-TNF therapy, and 3 meta-analyses on the topic of monotherapy versus combination therapy. [3] [4] [5] Using an iterative, modified Delphi panel approach, members rated 216 clinical scenarios for the appropriateness of combination therapy on a 1-9 scale (1-3 inappropriate, 4-6 uncertain, 7-9 appropriate) through a web-based survey, and then rerated the same scenarios after an in-person group discussion. Disagreement was assessed using a validated index, and scenarios with disagreement were automatically rated "uncertain."
Results
Panelists rated appropriateness of combination therapy in general, and concomitant azathioprine or methotrexate specifically with infliximab, injectable anti-TNFs (adalimumab and certolizumab pegol in CD, and adalimumab and golimumab in UC), and vedolizumab in 216 scenarios (Table 1) . Combination therapy with any IM was rated appropriate in half of all scenarios (107/216) and uncertain in the other half (103/216), with only 6 scenarios rated as inappropriate. Notably, treating young males or females (age <26) who have complicated CD with azathioprine plus any biologic was rated appropriate, even if they had previously failed IM therapy, as was treating young males with IM/biologic naive UC with either azathioprine or methotrexate plus anti-TNF therapy. By contrast, concomitant IM with vedolizumab in young males or females with UC and in males or females of any age with uncomplicated, IM/biologic naive CD was rated uncertain. Inappropriate use of combination therapy was limited to elderly patients with uncomplicated CD failing IM. Although agreement was not required, disagreement was noted in only 3 scenarios.
Discussion
In considering use of concomitant IM and biologic therapy in CD and UC, there was general consensus that concomitant azathioprine or methotrexate with antiTNFs is appropriate, except in special populations. Specifically, use in young males with uncomplicated disease, in young females using methotrexate, and in the elderly is uncertain, as is use of concomitant IM with vedolizumab in nearly all settings (Table 1) .
Several considerations arise when considering a treatment approach for a specific patient, including the need to balance benefits and risks of monotherapy or combination therapy, with limited data to guide clinical decision-making 9 ; risks of IBD biologic therapies have been recently reviewed 10 and are beyond the scope of the current work. However, an enriched evidence base and reassuring experience on the relative safety of combination therapy have reinforced the value of this approach in most patients with IBD. Furthermore, a reduced risk of antibody formation and infusion reactions has been associated with combination therapy when using infliximab. 3 However, the (albeit small) increased risk for lymphoma in young males and the elderly with combination therapy leaves clinicians wary of its use. Because methotrexate is not safe to use during pregnancy, it is unlikely that we will amass the evidence needed to erase the uncertainty of the value of combination therapy in young women.
Finally, we have seen an expanded treatment armamentarium in the past years with the addition of the first of a new class of anti-integrin therapy for both CD and UC. Given the lack of evidence for concomitant IM with vedolizumab, the uncertain rating for its use in nearly all scenarios across the age spectrum is not surprising.
Our study provides updated guidance for the treating clinician to delineate where concomitant IM is most (or least) appropriate. Given the many areas of uncertainty, it is clear that more data are needed to inform the optimal use of concomitant IM and biologic therapy in the current treatment paradigm for patients with IBD. 
